MacroGenics
MGNX
₹101.66
Share price
-6.30%
Change (1 day)
-70.40%
Change (1 year)
Categories
MacroGenics (MGNX) - Cash on Hand
Cash on Hand as of March 2025 : ₹13.16 Billion
According to MacroGenics's latest financial reports the company has ₹13.16 Billion in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
MacroGenics - Cash on Hand chart (from 2012 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | ₹17.30 B | -9.57% |
| 2023-12-31 | ₹19.13 B | 49.79% |
| 2022-12-31 | ₹12.77 B | -29.56% |
| 2021-12-31 | ₹18.13 B | -9.02% |
| 2020-12-31 | ₹19.93 B | 29.54% |
| 2019-12-31 | ₹15.38 B | -5.51% |
| 2018-12-31 | ₹16.28 B | -16.42% |
| 2017-12-31 | ₹19.48 B | 3.5% |
| 2016-12-31 | ₹18.82 B | -16.46% |
| 2015-12-31 | ₹22.53 B | 125.59% |
| 2014-12-31 | ₹9.98 B | 38.79% |
| 2013-12-31 | ₹7.19 B | 175.29% |
| 2012-12-31 | ₹2.61 B | -10.51% |
| 2011-12-31 | ₹2.92 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Xencor XNCR | ₹40.11 B | 204.63% | 🇺🇸 USA |
 Pfizer PFE | ₹1.479 T | 11,133.87% | 🇺🇸 USA |
 Merck MRK | ₹788.35 B | 5,886.73% | 🇺🇸 USA |
 Gilead Sciences GILD | ₹677.12 B | 5,042.05% | 🇺🇸 USA |
 Amgen AMGN | ₹752.64 B | 5,615.55% | 🇺🇸 USA |
 Eli Lilly LLY | ₹275.14 B | 1,989.45% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹1.006 T | 7,543.65% | 🇺🇸 USA |